Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death

OPEN

NEWS AND COMMENTARY

Citation: Cell Death and Disease (2015) 6, e1914; doi:http://dx.doi.org/10.1038/cddis.2015.242

Web End =10.1038/cddis.2015.242

& 2015 Macmillan Publishers Limited All rights reserved 2041-4889/15 http://www.nature.com/cddis

Web End =www.nature.com/cddis

H Sugimoto1, M Nakamura1, H Yoda2, K Hiraoka2, K Shinohara2, M Sang1, K Fujiwara3, O Shimozato1, H Nagase2 and T Ozaki*,1

Cell Death and Disease (2015) 6, e1914; doi:http://dx.doi.org/10.1038/cddis.2015.242

Web End =10.1038/cddis.2015.242 ; published online 15 October 2015

It has been well-known that human pancreatic cancer represents the fourth and fifth leading causes of cancer-related deaths in the United States and Japan, respectively.1,2

Notably, pancreatic cancer is characterized by high metastatic potential, resistance to chemotherapy and thus its prognosis is extremely poor with 5-year survival o5%. At diagnosis, more than 80% cases are already advanced and non-resectable.3

Therefore, chemotherapy and/or radiotherapy is the only option. Despite improvements in the treatments, the survival rate has not been significantly ameliorated over the last few decades. For chemotherapy, a deoxycytidine analog termed gemcitabine (GEM) is the first line of standard treatment given to most of the patients bearing advanced pancreatic cancer.4Unfortunately, GEM treatment provides limited clinical benefits, especially in advanced and metastatic disease.5 Hence, the extensive efforts to clarify the precise molecular mechanisms behind GEM-resistant phenotype of malignant pancreatic cancer and also to develop the promising strategies to enhance the efficacy of GEM should be required.

RUNX2 (Runt-related transcription factor 2) is one of the

RUNX family members implicated in the induction of osteo-blast differentiation and bone formation.6 Recently, we have found for the first time that RUNX2 attenuates p53/TAp73-dependent proper DNA damage response in p53-proficient human osteosarcoma-derived U2OS cells.7,8 On the basis of

our results, RUNX2 prohibited the transcriptional as well as pro-apoptotic activity of p53 through the complex formation with p53 in response to adriamycin (ADR). In addition, RUNX2 trans-repressed the transcription of TAp73 following ADR exposure. Thus, our recent studies strongly suggest thatRUNX2 has an oncogenic potential through the inhibition ofDNA damage-dependent cell death pathway mediated by proapoptotic p53/TAp73. Consistent with the above-mentioned our notion, it has been described that RUNX2 has an ability to transactivate a subset of its target genes involved in cancer cell migration and invasion.9

In the current study, we have focused on human pancreatic cancer cells. According to our present observations, p53-deficient pancreatic cancer AsPC-1 cells exhibited a much more higher resistance to GEM as compared with p53-

Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death

proficient pancreatic cancer SW1990 cells. Intriguingly, GEM treatment in AsPC-1 cells resulted in an induction and a reduction of pro-apoptotic TAp63 and pro-oncogenic RUNX2, respectively, indicating that there exists an inverse relationship between the expression levels of TAp63 and RUNX2 in response to GEM. Thus, it is likely that RUNX2 is capable to trans-repress TAp63 transcription. Indeed, forced expression of RUNX2 in AsPC-1 cells markedly suppressed the transcription of TAp63. Of note, close inspection of 5-upstream region of TAp63 gene revealed that there exists a putative

RUNX2-binding site (553 to 548).10 In addition, forced expression of TAp63 in AsPC-1 cells significantly reduced the number of G418-resistant colonies as compared with control cells transfected with the empty plasmid. These observations raised a possibility that RUNX2-mediated repression of TAp63 transcription might contribute to the acquisition and/or maintenance of GEM-resistant phenotype of ASPC-1 cells. To address this issue, siRNA-mediated knockdown of TAp63 inAsPC-1 cells was performed. Our siRNA against TAp63 efficiently reduced the expression of TAp63 but not of transactivation-deficient Np63. As expected, silencing ofTAp63 remarkably reduced the sensitivity of AsPC-1 cells toGEM relative to GEM-exposed non-silencing control cells. In support of these observations, depletion of TAp63 attenuatedGEM-dependent transactivation of a subset of p53/TAp63-target genes.

Considering that knockdown of RUNX2 significantly enhances ADR sensitivity of U2OS cells,7 we have examined whether silencing of RUNX2 could affect GEM sensitivity of AsPC-1 cells. On the basis of our present results, RUNX2 knockdown enhanced GEM sensitivity ofAsPC-1 cells accompanied by further accumulation ofTAp63 as well as a subset of its target genes in response toGEM, implying that RUNX2-mediated trans-repression ofTAp63 has a pivotal role in the regulation of GEM-resistant phenotype of p53-deficient pancreatic cancer cells (Figure 1). It is worth noting that depletion of TAp63 reduced GEM-mediated accumulation of DNA damage marker H2AX, whereas the amounts of H2AX was elevated in GEM-exposed RUNX2 knockdown cells.

1Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan; 2Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan and 3Innovative Therapy Research Group, Nihon University Research Institute of Medical Science, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi, Tokyo 173-8610, Japan*Corresponding author: T Ozaki, Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan. Tel: [phone]; Fax: [phone]; E-mail: mailto:[email protected]

Web End [email protected]

News and Commentary

2

Figure 1 Depletion of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death pathway

As DNA damage-mediated phosphorylation of H2AX is mediated by phosphorylated ataxia telangiectasia mutated (ATM),11 we have checked the phosphorylation status of ATM in the presence or absence of GEM. Our immunoprecipitation/immunoblotting experiments clearly demonstrated that GEM-mediated phosphorylation of ATM is abrogated in TAp63-silencing cells, suggesting that TAp63 participates in the regulation of ATM-dependent phosphor-ylation of H2AX following GEM exposure. However, the precise molecular mechanisms how TAp63 contributes to ATM-dependent phosphorylation of H2AX in response to GEM remain elusive. Further studies should be required to adequately address this issue.

Taken together, our present findings strongly suggest that RUNX2 attenuates TAp63-dependent cell death pathway in p53-deficient pancreatic cancer cells following GEM exposure, and thus the depletion of RUNX2 might be an attractive strategy to enhance the efficacy of the clinically approved GEM, which contributes to save cost to treat patients with advanced pancreatic cancer when compared with the development of novel anticancer drug(s) targeting pancreatic cancer.12

Conflict of InterestThe authors declare no conflict of interest.

1. Siegel R et al. CA Cancer J Clin 2014; 64: 929.2. Kuroda T et al. BMC Gastroenterol 2013; 13: 134.3. Smeenk HG et al. Langenbecks Arch Surg 2005; 390: 94103.4. Moss RA et al. Onco Targets Ther 2010; 3: 111127.5. Li Q et al. PLoS One 2014; 9: e104346.6. Komori T et al. Cell 1997; 89: 755764.7. Ozaki T et al. Cell Death Dis 2013; 4: e610.8. Ozaki T et al. FEBS J 2015; 282: 114128.9. Chimge NO et al. Oncogene 2013; 32: 21212130.10. Ito Y et al. Nat Rev Cancer 2015; 15: 8195.11. Falck J et al. Nature 2005; 434: 605611.12. Sugimoto H et al. Cell Death Discov 2015; 1: 15010.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the articles Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Web End =http://creativecommons.org/licenses/by/4.0/

Cell Death and Disease